WO 2005/074917 PCT/US2005/002559

-18-

CLAIMS

What is claimed is:

A method for treating diabetes in a subject, said method comprising:
admixing at least one phenserine compound or phenserine-like compound, and salts or esters thereof, and a pharmaceutically acceptable diluent, carrier or excipient to form a medicament; and administering the medicament to the subject, thereby treating diabetes in said subject.

10

20

- 2. The method according to claim 1, wherein the phenserine compound is selected from the group consisting of (-)-N-phenylcarbamoyl eseroline, (3aS)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate; (-)-2'-methylphenylcarbamoyleseroline,
- 15 (-)-2'-4'-dimethylphenylcarbamoyleseroline, (-)-4'methylphenylarbamoyleseroline, (-)-2'-ethylphenylcarbamoyleseroline, (-)-phenylcarbamoyleserolne, (-)-(-)-2',4',6'-trimethylphenylcarbamoyleseroline,
 - (-)-physovenol, (-)-5-O-(2'-methylphenylcarbamoyl)physovenol, (-)-3, 3a, 8, 8a-tetrahydro-3a, 8-dimethyl-2H-thieno-[2,3-b]indole-5-ol butyl carbamate, (-)-3, 3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indole-5-ol heptylcarbamate, (-)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indole-5-ol

(-)-2'-chlorophenylcarbamoyleseroline, (-)-2',6'-dichlorophenylcarbamoylseroline,

- phenylcarbamate,
- (-)-3,3a,8,8a-tetrahydro-3a,8-dimethyl,-2H-thieno[2,3-b]indole-5-ol
- 25 2'-methylphenylcarbamate,
 - (-)-3,3a,8,8a-tetrahydro-3a,8-dimethy-2H-thieno[2,3-b]indole-5-ol 2'-isopropylphenylcarbamate, (-)-thiaphysovenine, (-)-Phenylthiaphysovenine, and (-)-2',4'-dimethylphenyl-thiaphysovenine.
- 30 3. The method according to claim 2, wherein the phenserine-like compound is selected from the group consisting of donepezil, galantamine, rivastigme and tacrine.

WO 2005/074917 PCT/US2005/002559

-19-

4. The method according to claim 2, wherein the phenserine compound comprises (-)-N-phenylcarbamoyl eseroline or a salt or ester thereof.

- 5. The method according to claim 1, claim 2, claim 3 or claim 4, wherein treating diabetes comprises delaying onset of a cognitive impairment associated with diabetes.
 - 6. The method according to any one of claims 1-5, wherein treating diabetes comprises treating gestational diabetes.

10

- 7. The method according to any one of claims 1-6, wherein treating diabetes comprises a prophylactic treatment of diabetes.
- 8. The method according to any one of claims 1-7, wherein treating diabetes comprises treating cerebral angiopathy.
 - 9. The method according to any one of claims 1-8, wherein the subject is a human above the age of 60 years.
- 20 10. The method according to any one of claims 1-9, further comprising administering said phenserine compound or phenserine-like compound prior to a meal.
- 11. The method according to claim 10, further comprising coadministering a hypoglycemic agent selected from the group consisting of a sulfonylurea, a meglitinide, a biguanide, a thiazolidinedione, an alpha-glucosidase inhibitor and mixtures thereof.
- 12. The method according to any one of claims 1-11, wherein treating diabetes comprises treating at least one condition selected from the group consisting of hyperglycaemia, hypoglycaemia, response to hypoglycemic agents, diabetic

WO 2005/074917 PCT/US2005/002559

-20-

neuropathy, diabetic retinopathy, kidney function, vascular dementia, ketone levels, hyperlipidaemia, and coronary artery disease.

- 13. The method according to any one of claims 1-5, 7, and 9-12, wherein treating diabetes comprises treating insulin resistance.
 - 14. Use of an acetylecholinesterase antagonist for the preparation of a medicament useful in the treatment of complications associated with diabetes.
- 10 15. Use of the acetylcholinesterase antagonist of claim 14, wherein the acetylcholinesterase antagonist is phenserine.

15

- 16. Use of the acetylcholinesterase antagonist of claim 14 or claim 15 for the preparation of a medicament useful in the treatment of vascular dementia.
- 17. Use of the acetylcholinesterase antagonist of claim 14 or claim 15 for the preparation of a medicament useful in delaying the onset of diabetes associated cognitive impairment.
- 20 18. Use of the acetylcholinesterase antagonist of claim 14 or claim 15 for the preparation of a medicament useful in the treatment of insulin resistance.